Clinical outcome of various metformin treatments for women with polycystic ovary syndrome

Matsuzaki, Takashi; Tungalagsuvd, Altankhuu; Iwasa, Takeshi; Munkhzaya, Munkhsaikhan; Yano, Kiyohito; Mayila, Yiliyasi; Tokui, Takako; Yanagihara, Rie; Matsui, Shinji; Kato, Takeshi; Kuwahara, Akira; Irahara, Minoru

doi:10.1002/rmb2.12026

Cited by 5 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One population of women in whom metformin use was studied prior to and throughout pregnancy are those diagnosed with polycystic ovarian syndrome (PCOS). Few adverse outcomes from metformin use in PCOS offspring were reported [39]. Yet one study found larger head circumference in metformin-exposed PCOS offspring correlated with maternal obesity [40].…”

Section: Discussionmentioning

confidence: 99%

Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice

Garbarino

Santos

Nelson

et al. 2019

Pharmacological Research

View full text Add to dashboard Cite

Poorly managed gestational diabetes can lead to severe complications for mother and child including fetal overgrowth, neonatal hypoglycemia and increased autism risk. Use of metformin to control it is relatively new and promising. Yet safety concerns regarding gestational metformin use remain, as its long-term effects in offspring are unclear. In light of beneficial findings with metformin for adult mouse social behavior, we hypothesized gestational metformin treatment might also promote offspring sociability. To test this, metformin was administered to non-diabetic, lean C57BL/6J female mice at mating, with treatment discontinued at birth or wean. Male offspring exposed to metformin through birth lost social interaction preference relative to controls by time in chambers, but not by sniffing measures. Further, prenatal metformin exposure appeared to enhance social novelty preference only in females. However due to unbalanced litters and lack of statistical power, firm establishment of any sex-dependency of metformin's effects on sociability was not possible. Since organic cation transporter 3 (OCT3) transports metformin and is dense in placenta, social preferences of OCT3 knockout males were measured. Relative to wild-type, OCT3 knockouts had reduced interaction preference. Our data indicate gestational metformin exposure under non-diabetic conditions, or lack of OCT3, can impair social behavior in male C57BL6/J mice. Since OCT3 transports serotonin and tryptophan, impaired placental OCT3 function is one common mechanism that could persistently impact central serotonin systems and social behavior. Yet no gross alterations in serotonergic function were evident by measure of serotonin transporter density in OCT3, or serotonin turnover in metformin-exposed offspring brains. Mechanisms underlying the behavioral outcomes, and if with gestational diabetes the same would occur, remain unclear. Metformin's impacts on placental transporters and serotonin *

show abstract

Section: Discussionmentioning

confidence: 99%

Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice

Garbarino

Santos

Nelson

et al. 2019

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…Follicular development and ovulation rate increased (33) Metformin and saxagliptin Improved insulin sensitivity, metformin and combine drugs showed a reduced in total cholesterol level, metformin shows decrease in the LDL-C and increase in HDL-C levels (34) Cinnamon, metformin and darchini…”

Section: Metformin and Clomiphenementioning

confidence: 99%

The Efficacy of Metformin and Exenatide in Polycystic Ovary Syndrome (PCOS) Patients

Kesavan¹,

Chaudhry²,

Akim³

et al. 2023

Ars Pharm

View full text Add to dashboard Cite

Introduction: Polycystic Ovary Syndrome (PCOS) is a hormonal disorder that affects 5-10% of women who are their reproductive age. This meta-analysis aims to evaluate the efficacy of metformin and exenatide, respectively, and to compare the efficacy of both drugs using Body Mass Index (BMI), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and testosterone level. Method: Scopus, Science Direct, Oxford Journal, Wiley Online Library, and Medline (through the PubMed search engine) were used in this study. Statistical analysis of the included studies was done using the RevMan 5.4 software. Results: There were 6 studies included in the analysis of the study. There was a significant reduction in BMI of PCOS patients with exenatide versus metformin (mean difference = 0.51; 95% confidence interval (CI)= 0.07, 0.96, I 2= 52%; p=0.02). There was also a significant reduction in the testosterone level of PCOS patients with exenatide versus metformin (mean difference = 0.15; 95% confidence interval (CI)= 0.07, 0.22, I 2= 0%; p=0.0002). There was no effect on the mean of LDL-C and of HDL-C when compared between metformin and exenatide This meta-analysis shows that exenatide is effective in reducing BMI and testosterone levels in PCOS patients. Conclusions: There were a significant reduction in BMI and testosterone levels of PCOS patients when exenatide was used as compared to metformin. However, there was no effect on the mean of the LDL-C and HDL-C levels of the PCOS patients.

show abstract

Gestational diabetes mellitus - A metabolic and reproductive disorder

Choudhury

Rajeswari

2021

Biomedicine & Pharmacotherapy

185

View full text Add to dashboard Cite

Clinical outcome of various metformin treatments for women with polycystic ovary syndrome

Cited by 5 publications

References 26 publications

Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice

Prenatal metformin exposure or organic cation transporter 3 knock-out curbs social interaction preference in male mice

The Efficacy of Metformin and Exenatide in Polycystic Ovary Syndrome (PCOS) Patients

Gestational diabetes mellitus - A metabolic and reproductive disorder

Contact Info

Product

Resources

About